Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Abstract

In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE-TIMI 58 ClinicalTrials.gov number, NCT01730534 .).

Keywords

DapagliflozinMaceMedicineHazard ratioMyocardial infarctionInternal medicineType 2 diabetesDiabetes mellitusStroke (engine)PlaceboCardiologyHeart failureConfidence intervalEndocrinologyPercutaneous coronary intervention

MeSH Terms

AgedBenzhydryl CompoundsCardiovascular DiseasesDiabetes MellitusType 2FemaleGlucosidesHeart FailureHospitalizationHumansMaleMiddle AgedSodium-Glucose Transporter 2 Inhibitors

Affiliated Institutions

Related Publications

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray , Scott D. Solomon , Silvio E. Inzucchi +35 more

BACKGROUND In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through ...

2019 New England Journal of Medicine 6238 citations

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer , Stefan D. Anker , Javed Butler +36 more

Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure th...

2020 New England Journal of Medicine 4558 citations

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Vlado Perkovic , Meg Jardine , Bruce Neal +21 more

In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a med...

2019 New England Journal of Medicine 5513 citations

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Melanie J. Davies , David A. D’Alessio , Judith Fradkin +7 more

The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on...

2018 Diabetes Care 3378 citations

Decline in Cardiovascular Mortality

George A. Mensah , Gina S. Wei , Paul D. Sorlie +8 more

If the control of infectious diseases was the public health success story of the first half of the 20th century, then the decline in mortality from coronary heart disease and st...

2017 Circulation Research 785 citations

Publication Info

Year: 2018
Type: article
Volume: 380
Issue: 4
Pages: 347-357
Citations: 5890
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

5890

OpenAlex

191

Influential

5054

CrossRef

Cite This

APA Style

                            
                                
                                    Stephen D. Wiviott, 
                                
                                    Itamar Raz, 
                                
                                    Marc P. Bonaca
                                
                                et al.
                            
                            (2018). 
                            Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 
                            New England Journal of Medicine
                            , 380
                            (4)
                            , 347-357.
                            https://doi.org/10.1056/nejmoa1812389
                        

Identifiers

DOI: 10.1056/nejmoa1812389
PMID: 30415602

Data Quality

Data completeness: 90%